Exosens SA

As of June 30, 2026, EXOSENS SAS carries a market capitalization of 3.31B, placing it among publicly traded companies globally. Its enterprise value stands at 3.53B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

EXOSENS SAS's next confirmed earnings release is scheduled for February 22, 2027.

As of June 30, 2026, EXOSENS SAS has 203.73M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, EXOSENS SAS maintains a current ratio of 2.35, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of June 30, 2026, EXOSENS SAS holds 79.10M in cash and equivalents against 302.62M in total debt, resulting in a net debt position of 203.73M. Total book value stands at 515.12M, with working capital of 200.83M providing operational flexibility.